Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT02349438




Registration number
NCT02349438
Ethics application status
Date submitted
22/01/2015
Date registered
28/01/2015
Date last updated
19/06/2018

Titles & IDs
Public title
Assessment of Contact Lens Wettability Using Wavefront Aberrometry
Scientific title
Secondary ID [1] 0 0
CR-5685
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Visual Acuity 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - senofilcon A
Treatment: Devices - lotrafilcon B

Experimental: senofilcon A - The lenses will be worn for 2 hours in both eyes, and not dispensed

Active Comparator: lotrafilcon A - The lenses will be worn for 2 hours in both eyes, and not dispensed


Treatment: Devices: senofilcon A
A soft spherical contact lens

Treatment: Devices: lotrafilcon B
Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Higher Order Root Mean Square (HO RMS) - Near Target in Downgaze With Natural Blinking
Timepoint [1] 0 0
2 hours post insertion
Primary outcome [2] 0 0
Higher Order Root Mean Square (HO RMS) - Near Target in Downgaze With Controlled Blink
Timepoint [2] 0 0
2 hours post insertion
Primary outcome [3] 0 0
Higher Order Root Mean Square (HO RMS) - Distance Target in Primary Gaze With Controlled Blink
Timepoint [3] 0 0
2 hours post insertion

Eligibility
Key inclusion criteria
1. Healthy males or females that are at least 18 to no more than 40 years of age.

2. The subject must read, understand, and sign the Statement of Informed Consent and
receive a fully executed copy of the form.

3. The subject must appear able and willing to adhere to the instructions set forth in
this clinical protocol.

4. The subject must possess a wearable pair of spectacles with distance vision correction
which provide satisfactory vision.

5. The subject is a current spherical soft contact lens wearer (defined as a minimum of 6
hours of lens wear per week for a minimum of 1 month prior to the study) or has
sufficient prior experience with soft contact lens wear (defined as a minimum of 30
days of lens wear during the last 5 years).

6. The subject's vertexed best sphere distance refraction must be between -0.75 and -5.00
D in both eyes.

7. Cylinder refraction less than or equal to -0.75 D in both eyes (any axis).

8. The subject must have corrected visual acuity of 20/20 or better in each eye.
Minimum age
18 Years
Maximum age
40 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1. Currently pregnant or lactating (subjects who become pregnant during the study will be
discontinued).

2. Any ocular or systemic allergies or diseases that may interfere with contact lens
wear.

3. Any systemic disease, autoimmune disease, or use of medication, which may interfere
with contact lens wear.

4. Any known hypersensitivity or allergic reaction to contact lens solutions or sodium
fluorescein dye.

5. Any previous ocular or intraocular surgery (e.g. radial keratotomy, PRK, LASIK, etc.)

6. Current wearers of rigid or hybrid contact lenses.

7. Entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of
recurrent corneal erosions, aphakia, or moderate or above corneal distortion by
keratometry.

8. Infectious diseases (e.g. hepatitis, tuberculosis) or an immuno-suppressive disease
(e.g. HIV).

9. History of binocular vision abnormality or strabismus.

10. Employee of the investigational clinic (e.g. Investigator, Coordinator, Technician).

11. Clinically significant (grade 3 or 4) corneal edema, pterygium, corneal
vascularization, corneal staining, or any other abnormalities of the cornea or
conjunctiva which may interfere with the study measurements.

12. Strabismus, suppression or amblyopia.

13. Any ocular infection.

Study design
Purpose of the study
Basic Science
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


Intervention assignment
Crossover
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/12/2014
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/05/2015
Sample size
Target
Accrual to date
Final
25
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 0 0
- Kelvin Grove
Recruitment postcode(s) [1] 0 0
4059 - Kelvin Grove

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Johnson & Johnson Vision Care, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study will test the feasibility that differences in contact lens wettability can be
measured with a wavefront sensor.
Trial website
https://clinicaltrials.gov/ct2/show/NCT02349438
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT02349438